Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of vitamin D in cardiovascular health.

Critical reviews in clinical laboratory sciences·2026
Same author

Less Is More? Physical Inactivity and Increased Risk of Diabetes-Related Foot Ulceration-A Systematic Review.

Diabetes/metabolism research and reviews·2026
Same author

Exercise or Fasting in Individuals With Type 2 Diabetes Receiving Once-Weekly Basal Insulin Icodec.

Diabetes, obesity & metabolism·2026
Same author

A Validated, Modifiable Proteomic Score from the EXSCEL Trial Predicts Cardiovascular Events in Diabetes.

JCI insight·2026
Same author

Targeting Inflammation in Obesity and the Cardiovascular-Kidney-Metabolic (CKM) Syndrome Spectrum: A Narrative Review.

Obesity facts·2026
Same author

Erythrocyte and Platelet Indices at Admission and Discharge Stratify Long-Term Cardiovascular Risk After Invasive Treatment of Myocardial Infarction.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Jun 4, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.

Naveed Sattar1, Bruno Linetzky2, Giacomo Ruotolo2

  • 1School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.

Journal of the American College of Cardiology
|June 3, 2026
PubMed
Summary

Tirzepatide significantly improved cardiovascular risk biomarkers in people with obesity, including markers for inflammation, metabolic stress, and endothelial dysfunction. This study offers a comprehensive assessment of these long-term biomarker changes.

Keywords:
endothelial dysfunctioninflammationmetabolic/adiposity/hepatic stressthrombosistirzepatide

Related Experiment Videos

Last Updated: Jun 4, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Area of Science:

  • Cardiovascular Research
  • Metabolic Disease Research
  • Pharmacology

Background:

  • Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, is approved for type 2 diabetes and obesity.
  • The impact of tirzepatide on cardiovascular risk biomarkers in individuals with overweight or obesity requires further investigation.

Purpose of the Study:

  • To evaluate the effect of tirzepatide versus placebo on key biomarkers related to inflammation, metabolic/adiposity/hepatic stress, endothelial dysfunction, and hemostasis/thrombosis.
  • To assess these biomarker changes in participants with obesity over a 72-week treatment period.

Main Methods:

  • Plasma samples from the SURMOUNT-1 trial (n=392) were analyzed at baseline, 24, and 72 weeks.
  • Participants received placebo or tirzepatide (5, 10, or 15 mg) weekly.
  • Biomarker changes were assessed using mixed models for repeated measures, with primary outcomes at 72 weeks.

Main Results:

  • Tirzepatide significantly reduced high-sensitivity C-reactive protein, interleukin-6, homeostatic model assessment of insulin resistance, leptin, gamma-glutamyl transferase, fibroblast growth factor-21, and plasminogen activator inhibitor-1:Ag compared to placebo.
  • Significant improvements were also observed in adiponectin, free fatty acids, soluble intercellular adhesion molecule-1, E-selectin, and platelets at week 72 with tirzepatide.
  • No consistent associations were found for fibrinogen, tissue plasminogen activator:Ag, or thrombomodulin.

Conclusions:

  • Tirzepatide treatment was associated with improvements in biomarkers reflecting inflammation, metabolic/adiposity/hepatic stress, and endothelial dysfunction in individuals with obesity.
  • This analysis provides a comprehensive, long-term, randomized assessment of tirzepatide's effects on multiple cardiovascular pathways.